{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01971554: Phase 1 Interventional Completed Type 2 Diabetes Mellitus
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03450187: Phase 1 Interventional Completed Bacterial Infections
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00397566: Phase 2 Interventional Withdrawn HIV Infections
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity. Bristol-Myers Squibb was developing BMS-707035 for the treatment of HIV infections, however development was discontinued.
Status:
Investigational
Source:
NCT01469910: Phase 1 Interventional Completed Healthy
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03824795: Phase 2 Interventional Completed Clostridium Difficile Infection
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MGB-BP 3 is an antibacterial agent being developed by MGB Biopharma. This drug is now in phase II clinical trial to assess the safety, tolerability, and efficacy of incremental doses in patients with Clostridium difficile-associated diarrhea. In addition, this drug is studied for the treatment of Gram-positive infections; and skin and soft tissue infections.
Status:
Investigational
Source:
NCT04061421: Phase 1/Phase 2 Interventional Recruiting MDS/MPN
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02108756: Not Applicable Interventional Unknown status Bleeding Gastric Ulcer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Front Immunol. 2019;10:1275.: Not Applicable Human clinical trial Completed Psoriasis/blood/immunology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01668550: Phase 1 Interventional Terminated Advanced Solid Tumours
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AZD0424, a dual selective Src/Abl kinase inhibitor that has shown evidence of anti-tumor activity in pre-clinical studies. AZD0424 participated in phase I clinical trials in patients with advanced solid tumors, but this study was terminated because of insufficient evidence of efficacy as monotherapy.
Status:
Investigational
Source:
INN:denifanstat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
